哈药股份：控股股东累计质押股份约9.27亿股

Group 1 - The core point of the article is that Harbin Pharmaceutical Group Co., Ltd. (Harbin Pharmaceutical) has significant share pledges and a detailed breakdown of its revenue composition for 2024 [1] Group 2 - Harbin Pharmaceutical's controlling shareholder, Harbin Pharmaceutical Group Co., Ltd., holds approximately 1.173 billion shares, accounting for 46.58% of the total share capital [1] - The total pledged shares amount to approximately 927 million shares, which is 79% of the shares held by the controlling shareholder and 36.8% of the total share capital [1] - For the year 2024, the revenue composition of Harbin Pharmaceutical is as follows: wholesale medical customers 36.87%, pharmaceutical industry - health products 16.14%, chemical preparations 15.87%, wholesale commercial customers 13.99%, and pharmaceutical commercial - retail 10.46% [1] - As of the report, Harbin Pharmaceutical's market capitalization is 9.2 billion yuan [1]